Last reviewed · How we verify
Placebo matching ertugliflozin
Placebo matching ertugliflozin is a SGLT2 inhibitor Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Type 2 diabetes, Chronic kidney disease.
Ertugliflozin works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and promoting glucose excretion in the urine.
Ertugliflozin works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and promoting glucose excretion in the urine. Used for Type 2 diabetes, Chronic kidney disease.
At a glance
| Generic name | Placebo matching ertugliflozin |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
This leads to a decrease in blood glucose levels, making it easier for the body to use insulin. Ertugliflozin also has a mild diuretic effect, which can help reduce blood pressure and fluid overload in the body.
Approved indications
- Type 2 diabetes
- Chronic kidney disease
Common side effects
- Ketoacidosis
- Genital mycotic infections
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059) (PHASE3)
- ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure (PHASE2)
- ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF (PHASE4)
- Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004) (PHASE3)
- Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012) (PHASE3)
- Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016) (PHASE2)
- Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matching ertugliflozin CI brief — competitive landscape report
- Placebo matching ertugliflozin updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Placebo matching ertugliflozin
What is Placebo matching ertugliflozin?
How does Placebo matching ertugliflozin work?
What is Placebo matching ertugliflozin used for?
Who makes Placebo matching ertugliflozin?
What drug class is Placebo matching ertugliflozin in?
What development phase is Placebo matching ertugliflozin in?
What are the side effects of Placebo matching ertugliflozin?
What does Placebo matching ertugliflozin target?
Related
- Drug class: All SGLT2 inhibitor drugs
- Target: All drugs targeting SGLT2
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
- Indication: Drugs for Chronic kidney disease
- Compare: Placebo matching ertugliflozin vs similar drugs
- Pricing: Placebo matching ertugliflozin cost, discount & access